Dexcom is facing a class action suit related to G7 CGM
Dexcom faces a class action lawsuit alleging false and misleading claims about its G7 continuous glucose monitor.Summary
Dexcom is currently facing a class action lawsuit in the U.S. District Court for the Central District of California. The suit, led by plaintiff Kelly Grisoli, claims that the company’s representations regarding its G7 continuous glucose monitor (CGM) were “false, misleading, and deceptive” to consumers. Plaintiffs allege that Dexcom sold defective G7 CGMs prone to dangerous alert failures and subject to FDA recall, despite marketing the device as superior. This lawsuit follows closely after another class action against Dexcom was dismissed, which concerned alleged misrepresentation of sales efforts. The G7 CGM, cleared by the FDA in 2022, is a leading device in the market, offering improvements over its predecessor, the G6, including a smaller size and a reduced warmup period. Dexcom recently extended the G7’s wear time to 15 days.
(Source：MassDevice)